| Ytd | -1.04% | |
| 1y | 178.59% |
| Open | 9.58 | Prev Close | 9.50 | Low | 9.50 | High | 9.58 | Mkt Cap | 925.93M |
| Vol | 21.34M | Avg Vol | 1.80M | EPS | -0.63 | P/E | -15.08 | Forward P/E | -5.64 |
| Beta | 1.63 | Short Ratio | 2.05 | Inst. Own | 58.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.66 | 200-d Avg | 3.82 | 1yr Est | 9.50 |
PSTX News
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Pos
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseid
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the futur
Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show co
From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick,
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and th
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the futur
NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), h
Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding
Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal.
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Poseida (Nasdaq: PSTX) for possible breaches
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing,
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-A
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum invest
Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Friday, 431 companies hit new 52-week lows.
On Friday, 313 companies hit new 52-week lows.
On Thursday, 147 companies achieved new lows for the year.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
During Wednesday's morning trading, 400 companies set new 52-week lows.
During Friday's session, 445 companies made new 52-week lows.
Gainers AeroCentury Corp. (NYSE: ACY) shares climbed 414.9% to close at $13.85 on Monday after th